Table 5.
Qualitative IgG and IgM titers of the investigated viruses among patients with long-COVID syndrome and healthy (non-infected, unvaccinated) controls.
| Healthy (n = 105) | Long-COVID (n = 105) | p value | |
|---|---|---|---|
| Male | 38 (36.2%) | 38 (36.2%) | |
| Cumulative virus IgM positivity | 7 (6.7%) | 19 (18.1%) | 0.02 |
| CMV IgG positivity | 60 (57.1%) | 59/103 (57.3%) | |
| CMV IgM positivity | 1 (1%) | 4/103 (3.9%) | |
| EBV IgG positivity | 100 (95.2%) | 103 (98.1) | |
| EBV VCA IgG positivity above detection limit | 25 (23.8%) | 42 (40.0%) | 0.018 |
| EBV IgM positivity | 2 (1.9%) | 7 (6.7%) | |
| EBV EBNA IgG positivity | 91 (86.7%) | 100 (95.2%) | |
| EBV EBNA IgG above detection limit | 21 (20%) | 18 (17.1%) | |
| HSV IgG positivity | 87 (82.9%) | 82/104 (78.8%) | |
| HSV IgG positivity above detection limit | 44 (41.9%) | 40/104 (38.5%) | |
| HSV IgM positivity | 2 (1.9%) | 6/104 (5.8%) | |
| VZV IgG positivity | 105 (100%) | 98/101 (97%) | |
| VZV IgM positivity | 2 (1.9%) | 1/101 (1%) | |
| Parvo_B19 IgG positivity | 91 (86.7%) | 86 (81.9% | |
| Parvo_B19 IgG positivity above detection limit | 24 (22.9%) | 14 (13.3%) | |
| Parvo_B19 IgM positivity | 1 (1%) | 6 (5.7%) |
Comparisons were performed by using a two-sided χ2 test.
Bold values represent significant differences between healthy and long-COVID patient groups.